Literature DB >> 738122

Platelet-mediated pulmonary hypertension and hypoxia during pulmonary microembolism: reduction by platelet inhibition.

J Mlczoch, A Tucker, E K Weir, J T Reeves, R F Grover.   

Abstract

The literature indicates that vasoactive substances released from platelets contribute to the pulmonary pressor response and hypoxemia during pulmonary microembolism. Hence, removal of the platelets or inhibition of their function should reduce these effects. The purpose of this study was, therefore, to investigate the pulmonary effects of experimental embolism with glass beads in dogs rendered thrombocytopenic with platelet antiserum and to compare these effects to the effects in dogs pretreated with sulfinpyrazone (Anturane) or heparin, both substances that affect the function of platelets, probably by inhibiting the release of platelets. In all three groups the pulmonary hypertension was reduced by more than half, and hypoxemia was lessened or abolished. The results of this study indicate the platelets contribute to the effects of pulmonary microembolism and that administration of sulfinpyrazone or heparin reduces the embolism-induced pulmonary hypertension to the same extent as the depletion of platelets. Platelet-inhibiting drugs might therefore be useful prophylactically in human pulmonary microembolism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 738122     DOI: 10.1378/chest.74.6.648

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 2.  Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: a report of four patients and review of the literature.

Authors:  Oded Szold; Wisam Khoury; Philippe Biderman; Joseph M Klausner; Pinchas Halpern; Avi A Weinbroum
Journal:  Lung       Date:  2006 Jan-Feb       Impact factor: 2.584

3.  Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism.

Authors:  W V Huval; M A Mathieson; L I Stemp; B M Dunham; A G Jones; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1983-02       Impact factor: 12.969

4.  Thrombi in antrum atrii dextri of human heart as clinically important source for chronic microembolisation to lungs.

Authors:  T N James
Journal:  Br Heart J       Date:  1983-02

5.  Dipyridamole treatment in chronic obstructive airways disease: effect on platelet regeneration time.

Authors:  E Tremoli; L Bertoli; R Merlini; S Colli; P Maderna; O Mantero; C R Sirtori
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine.

Authors:  M D McGoon; P M Vanhoutte
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

7.  Platelet activation in experimental murine neonatal pulmonary hypertension.

Authors:  Pavel Davizon-Castillo; Ayed Allawzi; Matthew Sorrells; Susan Fisher; Kristina Baltrunaite; Keith Neeves; Eva Nozik-Grayck; Jorge DiPaola; Cassidy Delaney
Journal:  Physiol Rep       Date:  2020-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.